Bausch + Lomb Corporation will report its fourth-quarter and full-year 2025 financial results on Wednesday, February 18, 2026. The announcement will include a detailed breakdown of revenue by segment—contact lenses, ophthalmic pharmaceuticals, surgical devices and over-the-counter products—as well as commentary on geographic performance across North America, Europe and emerging markets. Management is expected to discuss year-over-year trends in core operating profit margins and outline factors driving growth, such as new product launches and market share gains in premium contact lenses.

The company will host an investor conference call and live webcast at 8:00 a.m. Eastern Time on the day of the release. Dial-in numbers include +1 (888) 506-0062 for North America and +1 (973) 528-0011 for international participants, with access code 923960. A replay will be available through March 4, 2026, via +1 (877) 481-4010 (North America) or +1 (919) 882-2331 (international), passcode 53392. All presentation slides and supplemental materials will be posted in advance on the Investor Relations section of the Bausch + Lomb website.

Investors will be watching for management’s guidance for 2026, including anticipated R&D spending on next-generation surgical devices and planned marketing investments in emerging regions such as Latin America and Asia-Pacific. The update is also likely to address supply-chain initiatives aimed at reducing unit costs in the contact lens division and progress toward achieving the company’s medium-term targets for adjusted EBITDA growth. Shareholders should consider potential headwinds from foreign-exchange fluctuations and regulatory developments in key markets when evaluating the outlook.